View in EDS

1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors.

Saved in:
Bibliographic Details
Title: 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors.
Authors: Chauhan, A.1 (AUTHOR), Reis, I.2 (AUTHOR), Jani, C.T.3 (AUTHOR), Modak, R.1 (AUTHOR), Bilbao, D.4 (AUTHOR), Merchan, J.R.5 (AUTHOR), Lopes, G.6 (AUTHOR), Hosein, P.7 (AUTHOR), Hallenbeck, P.8 (AUTHOR), Trinh, H.9 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1019-S1019. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.08.2361